ICH plan to reduce rat carcinogenicity studies moves into new phase
This article was originally published in Scrip
International plans to reduce the need for the two-year rodent carcinogenicity test, and thereby possibly reduce drug development timelines and increase speed to market, are among the issues to be discussed at the International Conference on Harmonization (ICH) meeting next month in Osaka, Japan.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.